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ABSTRACT 
Systemic amyloidosis is a fatal disorder caused by pathological extracellular 
deposits of amyloid fibrils that are always coated with the normal plasma protein, 
serum amyloid P component (SAP). The small-molecule drug, miridesap, [(R)-1-[6-
[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid 
(CPHPC)] depletes circulating SAP but leaves some SAP in amyloid deposits. This 
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residual SAP is a specific target for dezamizumab, a fully humanized monoclonal 
IgG1 anti-SAP antibody that triggers immunotherapeutic clearance of amyloid. We 
report the safety, pharmacokinetics, and dose-response effects of up to three 
cycles of miridesap followed by dezamizumab in 23 adult subjects with systemic 
amyloidosis (ClinicalTrials.gov identifier: NCT01777243). Amyloid load was 
measured scintigraphically by amyloid-specific radioligand binding of 123I-labeled 
SAP or of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid. Organ extracellular 
volume was measured by equilibrium magnetic resonance imaging and liver 
stiffness by transient elastography. The treatment was well tolerated with the main 
adverse event being self-limiting early onset rashes after higher antibody doses 
related to whole body amyloid load. Progressive dose-related clearance of hepatic 
amyloid was associated with improved liver function tests. 123I-SAP scintigraphy 
confirmed amyloid removal from the spleen and kidneys. No adverse cardiac events 
attributable to the intervention occurred in the six subjects with cardiac 
amyloidosis. Amyloid load reduction by miridesap treatment followed by 




The extracellular accumulation of amyloid fibrils disrupts the architecture and function of 
affected tissues and organs in systemic amyloidosis, causing fatal disease (1). Systemic 
amyloid deposits usually do not elicit inflammation or the physiological phagocytic 
mechanisms that normally clear extracellular protein and cellular debris. Current 
management of systemic amyloidosis comprises support for damaged amyloidotic organs, 
coupled with attempts to reduce production of amyloidogenic proteins. Even if fibril 
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precursor abundance is sufficiently reduced, thereby arresting new amyloid accumulation, 
existing amyloid is cleared slowly and variably. Efforts to develop targeted 
immunotherapeutic clearance of amyloid are therefore underway (2, 3). 
Human serum amyloid P component (SAP) from the plasma is present in all human 
amyloid deposits due to its avid but reversible binding to amyloid fibrils of all types (4). Our 
small­molecule drug, miridesap [(R)­1­[6­[(R)­2­carboxy­pyrrolidin­1­yl]­6­oxo­hexanoyl] 
pyrrolidine­2­carboxylic acid], previously known as CPHPC, swiftly depletes circulating 
SAP (5) but leaves some SAP in amyloid deposits (6). The residual SAP acts as a specific 
antigen target for therapeutic anti­SAP antibodies that can bind to it and thereby trigger 
amyloid removal (2, 3). Plasma SAP depletion by miridesap is essential before anti­SAP 
antibody administration to avoid formation of potentially proinflammatory circulating 
immune complexes. In humanized murine models, binding of anti­SAP antibodies to 
amyloid activates the classical complement pathway and opsonizes the deposits with fixed 
complement C3, attracting and engaging macrophages that fuse into multinucleated giant 
cells uniquely able to surround, engulf, and destroy large complement opsonized objects 
(2, 7). 
We have recently reported safety and clinical proof­of­concept results for miridesap 
followed by the fully humanized monoclonal anti­human SAP antibody, dezamizumab, in 
patients with different forms of systemic amyloidosis, including the following types: 
monoclonal immunoglobulin light chain (AL), reactive systemic amyloid A protein (AA), 
apolipoprotein AI (AApoAI), and fibrinogen A α­chain (AFib) (3). Infusion of anti­SAP 
antibody triggered transient early inflammatory cytokine production and an acute phase 
response, followed by substantial plasma C3 depletion, but there was no new or increased 
renal or other organ dysfunction (3). Amyloid clearance from the liver was associated with 
improved liver function tests (3). However, maximal removal of amyloid from all organs 
and tissues, which will be required for optimal clinical efficacy, was not achieved with just 
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a single dose of anti­SAP antibody. Here, we investigated the safety, tolerability, and 
efficacy of up to three cycles of treatment with miridesap followed by dezamizumab in 23 
adult subjects with systemic amyloidosis (15 participated in the previous study, whereas 
8 were new subjects). 
 
RESULTS 
Patient characteristics, trial design, and safety data 
We conducted the second part, designated part B, of an open­label, nonrandomized, first 
in human, phase 1 clinical trial of miridesap followed by dezamizumab in 23 patients with 
systemic amyloidosis: 12 with AL, 5 with AFib, 3 with transthyretin type (ATTR), 2 with AA, 
and 1 with AApoAI. Their demographic features, amyloid distribution and load, 
dezamizumab doses, and rationale thereof, are shown in table S1. Fifteen of the subjects 
had previously received a single treatment with miridesap followed by dezamizumab in 
the first part of the trial, designated part A, which has been reported elsewhere (3), and 
eight additional subjects were newly recruited for part B. Among 48 total treatments 
administered to the 23 trial subjects, each with completed follow­up, 8 subjects received 
1 treatment, 5 subjects received 2 treatments, and 10 subjects received 3 treatments. 
There were no deaths during the study, no withdrawals during treatment sessions, 
and no signs of organ toxicity. Injection of miridesap caused mild, transient, non­treatment 
limiting, local pain and occasional erythema on four occasions, and there were 11 mild 
adverse events related to intravenous catheter insertion. There were also three serious 
adverse events. Subject 008 became hypotensive immediately after dezamizumab 
infusion and recovered but then had tachycardia with blood pressure around 90/60 mmHg 
about 4 hours later due to insufficient fluid replacement. A temporary increase in serum 
creatinine concentration thereafter had returned to baseline at day 21. Subject 021 
developed an erythema multiform­like rash, starting within 24 hours of dezamizumab 
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infusion and resolving gradually without sequelae after 60­mg oral prednisolone. Subject 
018, with a history of episodic atrial fibrillation, had a spontaneously resolving episode of 
fast atrial fibrillation 27 days after dezamizumab infusion that was not considered related 
to study treatment. 
Dose­related infusion reactions to dezamizumab consisted of one or more of the 
following: headache, flushing, feeling hot or cold, chest discomfort, chills, facial, orbital, 
and peripheral edema, nausea, vomiting, diarrhea, fatigue, tachycardia, presyncope, and 
hypotension. None were reported at ≤650 mg in part B of the trial, but they occurred in 
20% of patients receiving 1000 to 1200 mg and 50% of patients receiving 2000 mg. 
However, although not formally comprising an infusion reaction, some of these symptoms 
were reported within 24 hours of dezamizumab administration after 50% of doses at 
≤650 mg, 67% of doses at 1000 to 1200 mg, and 75% of doses at 2000 mg. Slowing and 
interrupting the infusion was helpful and, together with premedication with hydrocortisone 
and antihistamine, enabled dezamizumab dosing up to 2000 mg in subjects with heavy 
amyloid loads and 1200 mg in those with small or moderate amyloid loads. In cardiac 
amyloidosis, dezamizumab administration split over 2 days caused no adverse cardiac 
events. 
Twenty two of 38 recipients of ≥600 mg of dezamizumab developed mild or 
moderate urticarial or macular rashes, usually within 24 to 36 hours, but there were no 
associated systemic symptoms, signs, or related test results, or any mucosal involvement. 
Urticaria responded well to antihistamines. Macular lesions were more persistent but 
resolved spontaneously without sequelae. Rash incidence generally increased with 
increasing dezamizumab dose and was most common in subjects with a small or 
moderate amyloid load given higher doses that produced the highest peak plasma 
concentrations of dezamizumab. The rash recurred on repeat dezamizumab 
administration but was not necessarily more severe. Two skin biopsies were obtained. 
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One showed active leukocytoclastic vasculitis but neither fibrinoid change or necrosis nor 
detectable immune complexes, immunoglobulin, or complement deposition. The other 
skin biopsy showed only nonspecific changes. The rash appearance within 48 hours of 
dezamizumab infusion, rapidly peaking in severity, corresponded with the transient peak 
circulating concentration of the antibody and, together with the mild vasculitic histology 
without deposited immunoreactants, suggested that circulating proinflammatory 
complexes or aggregates derived from dezamizumab might be responsible. Dividing the 
planned dezamizumab infusion over 2 days enabled the second portion of the dose to be 
omitted in two subjects who developed a rash soon after the first exposure. 
No other adverse effects were attributable to dezamizumab treatment. The acute 
phase response and complement consumption that always preceded amyloid clearance 
were not associated with any organ dysfunction. Battery­operated, portable, continuous 
electrocardiography (EKG) recordings (Holter monitoring) showed no clinically significant 
abnormalities. No urine sediment abnormalities were seen, and renal function was stable 
in all subjects, except for subject 008 as noted above. 
 
Pharmacokinetics of miridesap and dezamizumab in patients with systemic 
amyloidosis 
Circulating miridesap concentrations were consistent with previous clinical miridesap 
studies (5, 6, 8). The regimen reduced baseline plasma SAP concentrations in all subjects 
to the target value of <2 mg/liter before dezamizumab was administered. Plasma SAP 
values had returned to the reference range at day 42. 
In subjects with a heavy amyloid load, including hepatic amyloidosis, the circulating 
dezamizumab concentration typically fell to <50 µg/ml within 24 hours, even after the 
2000­mg dose. With small to moderate amyloid loads, without liver involvement, the 
24­hour concentration was about 150 µg/ml, falling to <50 µg/ml by 72 hours. After 
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reduction of hepatic amyloid load by previous dezamizumab treatment, clearance of a 
subsequent antibody dose was slower, consistent with the rate depending on 
target­specific binding to amyloid­ associated SAP (Fig. 1). 
 
Progressive amyloid removal in patients treated with miridesap followed by 
dezamizumab 
In the first part of the trial (part A), single doses of 246 to 650 mg of dezamizumab 
substantially cleared hepatic amyloid in five subjects with moderate or heavy liver load, 
leading to improved liver function tests, but amyloid removal was generally not detected 
in those with the heaviest liver and whole­body amyloid loads (3). In the second part of 
the trial (part B), which is reported in this study, there was evidence of liver amyloid 
reduction in some subjects who received 1000 to 1200 mg of dezamizumab but not in 
other subjects with the heaviest load. However, a 2000­mg dose reduced amyloid load in 
the liver and/or spleen in five of seven subjects who received it, confirmed by 123I­labeled 
SAP scintigraphy (Fig. 2, A and B, and Table 1). The proportions of 123I­SAP tracer 
retained in the liver at 24 hours, corresponding to the Fig. 2A images, were 76.0% 
pretreatment, 58.5% after the first dose, and 20.0% after the second dose. The exceptions 
were AL subject 011, whose clone relapsed causing new amyloid accumulation, and 
subject 019 who only received a single 2000­mg dose (Table 1). Apart from the latter 
patient, the amyloid load was reduced in the liver and/or other organs after one, two, or 
three doses of dezamizumab in the other nine participants who had liver amyloid. For 
example, Fig. 2B shows reduction in amyloid load in the spleen and kidneys of subject 
017. The proportions of 123I­SAP tracer retained at 24 hours in the spleen and kidneys 
were 5.3 and 8.2% before and 3.8 and 5.7% at day 42 after treatment. Amyloid clearance 
was always preceded by plasma C3 depletion during the first week after dezamizumab 
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infusion, with the C3 concentration falling to between 23 and 87% of predose values after 
the 14 treatments in these nine subjects. 
Reductions in liver amyloid load detected by SAP scintigraphy were independently 
corroborated by equilibrium magnetic resonance imaging (MRI) measurements of the 
liver. The volume of the extra­ cellular space, where the amyloid is located, decreased 
toward normal in all cases. However, liver stiffness, which is markedly increased by 
amyloid, was the most sensitive marker for hepatic amyloid. Stiffness initially increased in 
some subjects (Fig. 3A), consistent with the massive early infiltration of macrophages into 
amyloid deposits seen in the mouse model (2). However, liver stiffness then fell 
substantially (Fig. 3A), consistent with amyloid clearance and the accompanying 
resolution of the cellular infiltrate reported in that animal model (2). 
Subjects 011 and 013 with AL amyloidosis, who suffered clonal relapses after 
receiving their antibody dose in part A, and AL subject 014 who relapsed after a second 
dose in part B, accumulated additional amyloid between dosing sessions. In subject 109, 
with hereditary AApoAI amyloidosis and continuous production of amyloidogenic 
apolipoprotein AI, there was evidence of amyloid removal after each dose, followed by 
some amyloid reaccumulation. Nevertheless, liver function was closer to normal after the 
third treatment compared to the original baseline (Table 1). 
 
Reduction in renal amyloid in patients treated with miridesap followed by 
dezamizumab 
Reduction in renal amyloid was observed in 7 of 11 subjects with renal amyloid detected 
by SAP scintigraphy (five with AFib and one each with AL and AA amyloidosis), generally, 
those treated with higher doses of dezamizumab. SAP scintigraphy showed renal amyloid 
reduction in zero of six subjects after <600 mg of dezamizumab, two of six (33%) after 600 
to 650 mg, and five of six (83%) after 1200 mg (Fig. 2B and table S1). Renal amyloid 
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clearance was only seen in the AL case, subject 013, after a first dose of dezamizumab 
had cleared this patient’s hepatic amyloid. The AFib patients had small to moderate 
whole­body amyloid loads with no detectable liver amyloid. Renal function, serum 
creatinine and urea concentrations, and urinary protein excretion were unchanged in all 
subjects up to day 42, the end of the protocol follow­up, similar to what we previously 
documented for subjects in part A, the initial phase of the trial (3). 
 
Preliminary safety data in patients with cardiac amyloidosis 
Patients with clinical cardiac amyloidosis were specifically excluded in part A for safety 
reasons (3). After establishing additional safety information in part B, three subjects with 
AL and three with ATTR cardiac amyloidosis were enrolled for preliminary assessment 
(Table 2). No actual infusion reactions occurred, but there were some modest systemic 
symptoms. Crucially, there were no new arrhythmias, no increase in circulating troponin T 
or creatine kinase concentrations, and no change in existing cardiac abnormalities. 
Nevertheless, on day 1 after antibody dosing, four of these subjects developed transient, 
up to fivefold, increases in the circulating concentration of N­terminal pro–B­type 
natriuretic peptide (NT­proBNP), lasting about 1 week (Fig. 3C), suggesting possible 
engagement of the target mechanism in the heart. One subject (021) who received three 
antibody doses showed a reduction of 17% in left ventricular mass by cardiac MRI, greater 
than the coefficient of variation of the method, suggesting reduction in cardiac amyloid 
load (Table 2). 
 
DISCUSSION 
Systemic amyloidosis is usually diagnosed late after the initial clinical presentation, when 
organ function is often already severely compromised. There have been major advances 
in cytotoxic chemotherapy to eliminate the B cell or plasma cell dyscrasias that cause AL, 
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the most common type of systemic amyloidosis but, unfortunately, not all patients tolerate 
these toxic regimens or respond to them. About 25% of AL patients still die within the first 
6 months after diagnosis and, even when there is a clonal response, regression of amyloid 
is slow and variable. AA amyloidosis is now rare, and the various underlying inflammatory 
disorders that cause it can usually be controlled, but amyloid regression is still slow and 
often limited. Furthermore, there are currently no approved means of reducing production 
of transthyretin, the amyloidogenic protein in senile and hereditary ATTR amyloidosis, or 
the amyloidogenic proteins in other types of hereditary amyloidosis, apart from liver 
transplantation in AFib (9). Thus, although reduction of amyloid fibril precursor proteins 
will always be desirable, there is an urgent need for treatment that removes amyloid from 
the tissues. 
Here, we show that dezamizumab, infused after previous depletion of plasma SAP 
by miridesap, achieves this objective with acceptable safety. Serial doses, comprising 
sufficient dezamizumab in relation to each subject’s amyloid load, progressively removed 
amyloid from the liver, spleen, and kidneys in acquired and hereditary systemic 
amyloidosis. Amyloid clearance from the liver was faster and more extensive than from 
other organs, as previously observed with spontaneous hepatic AA and AL amyloid 
regression in effectively treated patients (10–13). This may reflect the fact that the 
sinusoidal, fenestrated hepatic capillary endothelium allows unhindered access of 
antibodies and complement proteins from the blood to the extracellular space where the 
amyloid deposits are located. Although splenic capillaries also have sinusoidal 
endothelium, both spontaneous amyloid regression and amyloid clearance by miridesap 
plus dezamizumab are slower in the spleen, so there may be other factors, such as 
availability of appropriate macrophage populations. Amyloid clearance from the heart, 




Classical complement pathway activation, which is required in the mouse model to 
engage macrophages and enable amyloid removal (2), requires a multimeric assembly of 
bound antibody molecules (14). The effective dezamizumab doses observed in this study 
were consistent with the requirement to form these assemblies on the amounts of target 
SAP available in each individual’s amyloid, and only dezamizumab doses that triggered 
plasma C3 depletion produced detectable amyloid clearance. However, regardless of the 
mechanism, our results indicate that (i) repeated, sufficient doses of dezamizumab should 
substantially clear amyloid of all types, and (ii) repeated treatments will be required if 
amyloid accumulation continues when amyloidogenic fibril precursor production cannot be 
controlled. 
Clearance of amyloid from the liver was associated with improved liver function, 
firmly establishing the relationship between the presence and amount of amyloid and the 
pathogenesis of organ dysfunction. There was no change in proteinuria or renal function 
through the 6­week study follow­up; additional dosing and longer follow­up will be required 
to ascertain preservation or restoration of renal function. Encouraging safety and 
tolerability data were also obtained in the preliminary study of cardiac AL and ATTR 
amyloidosis. There was no evidence of myocardial damage, but early transient increases 
in plasma NT­proBNP concentration after dezamizumab administration suggested that the 
antibody may be initiating the mechanism for potential amyloid clearance in the heart. A 
forthcoming larger study of serial anti­SAP dosing at regular and closer intervals will seek 
to extend safety and establish efficacy in cardiac amyloidosis, which is the major single 
cause of morbidity and mortality. 
No direct adverse effect of dezamizumab on organ function was detected but, as 
previously reported for part A, systemic infusion reactions to effective doses were 
universal. They were substantially reduced by antihistamine and hydrocortisone 
premedication and were further mitigated by divided slow infusion of larger total antibody 
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doses, enabling use of up to the 2000­mg maximum dose. Nevertheless, total doses of 
>600 mg caused pleomorphic urticarial and macular skin rashes in most recipients, with 
the time course suggesting causation by circulating proinflammatory materials derived 
from dezamizumab. However, the identified and potential risks of the intervention are 
considered manageable, and thus acceptable, in relation to the demonstrable clinical 
benefits of removing amyloid from vital organs. There are several limitations to our study. 
Only 23 subjects have been treated hitherto, so that the scope and scale of potential 
adverse reactions, especially to larger and repeated doses of dezamizumab, cannot yet 
be reliably estimated. Despite unequivocal evidence of reduction in renal amyloid load, 
effects on proteinuria and preservation of renal function will require a longer follow­up than 
the 6 weeks of the present protocol. Other than preliminary examination of safety in the 
six cardiac amyloidosis patients reported in this study, the use of miridesap and 
dezamizumab in subjects with heart involvement will be explored in our forthcoming phase 
2 trial. 
Clinical trials in AL amyloidosis of two different anti­amyloid antibodies, NEOD001 
(Prothena) (15) and 11­1F4 (Columbia) (16), have reported improvements in some 
biochemical markers of cardiac function but did not evaluate amyloid removal. NEOD001 
does not elicit any systemic reaction and, in contrast to the rapid amyloid load­related 
clearance of dezamizumab, the 13­ to 16­day plasma half­life of NEOD001 approaches 
that of free immunoglobulin G (15). Infusion of 11­1F4 produces systemic reactions and 
rashes and the antibody demonstrably bound to amyloid in 9 of 18 reported AL cases (17). 
Further observations are required on amyloid clearance and the clinical effects produced 





MATERIALS AND METHODS 
Study design 
The two center [Quintiles and GlaxoSmithKline (GSK) Clinical Unit], open­label, 
nonrandomized, first in human study of the fully humanized monoclonal IgG1 anti­SAP 
antibody (GSK2398852, dezamizumab) administered after previous infusion of miridesap 
(CPHPC) was approved by the UK Medicines and Healthcare Products Regulatory 
Agency and the Berkshire “B” phase 1 accredited Research Ethics Committee. Each 
dosing session comprised visits for baseline measurements, inpatient treatment, and 
scheduled outpatient assessments with a follow­up at 6 weeks after dezamizumab dosing 
for evaluation of amyloid load. Part A, an initial single­dose escalation study reported 
previously, established safety and proof of mechanism (3). Part B, reported in this study, 
adaptively extended antibody dosing, evaluating up to three treatments at intervals of at 
least 2 months. Some part A subjects proceeded to part B, for which additional subjects 
were also recruited. Patients with known cardiac amyloidosis were excluded from part A 
but, after the acceptable initial safety profile, were included in part B, provided that there 
was no systolic impairment, New York Heart Association class III/IV decompensated 
cardiac failure, recent cardiac­related syncope or presyncope, or circulating NT­proBNP 
>1800 ng/liter in AL amyloidosis. 
 
Participants 
Comprehensively characterized, biopsy­proven, systemic amyloidosis patients (n = 23, 
11 female), aged 44 to 69 years (table S1), and under the care of the UK National Health 
Service National Amyloidosis Centre at the Royal Free Campus of University College 
London were referred for screening. All gave written informed consent, had adequate 
venous access, and could tolerate the study protocol. Entry to the study required 
14 
 
compliance with stringent requirements for functional status and organ function but did not 
have constraints regarding previous treatment. Twelve subjects had AL amyloidosis, all of 
whom had completed chemotherapy with either complete or good partial responses, and 
all had good functional status, but three of them suffered typical clonal relapses during the 
study. Two subjects had AA amyloidosis, but their underlying inflammatory conditions 
were in complete remission and they, together with the remaining nine subjects with 
hereditary AFib, ATTR, or AApoAI amyloidosis, had received only supportive care. 
 
Anti-SAP antibody intervention 
Subjects were admitted for initial plasma SAP depletion, typically by 3 days intravenous 
infusion of 20­mg/hour miridesap (8), to reach the selected target of <2 mg/liter. 
Dezamizumab was then infused intravenously, designated as study day 1. Miridesap 
administration was continued by subcutaneous injection, typically for 11 days, to maintain 
circulating SAP depletion until plasma anti­SAP antibody activity had disappeared. The 
miridesap dose of 60 mg, three times a day, was adjusted for renal impairment, if 
necessary, to keep predicted exposure below pre­established protocol­defined safety 
limits (8). 
Premedication with 100 mg of parenteral hydrocortisone and an antihistamine 
substantially mitigated the otherwise dose­limiting reactions caused by infusion of more 
than 200 mg of dezamizumab in part A, allowing administration of higher doses, and was 
routinely used in part B. The highest antibody dose was 1200 mg in subjects with small to 
moderate amyloid load and 2000 mg in those with large whole­body load involving the 
liver. Repeat treatment depended on toleration of, and response to previous dose(s), and 
subject availability to comply with the protocol. Each treatment was a discrete event with 
a minimum interval between doses of 2 months, enabling completion of follow­up and 
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evaluation of response (interval range, 4 to 19 months for part A subjects in part B; and 2 
to 3 months for part B–only participants). 
 
Global dosing strategy and individual subject dosing rationale 
Table S1 shows each dezamizumab dose and its rationale. Dose response was initially 
explored in part A subjects who had shown evidence of hepatic amyloid removal. The 
decision to administer second or third doses was based on tolerability and response to the 
previous dose and subject availability, given the substantial time commitment. Each 
treatment was a discrete event and the interval between doses was variable, ranging from 
5 to 19 months between first and second treatments in the part A subjects and 2 to 5 
months in the part B–only participants. 
Reduction in hepatic amyloid was observed in five subjects in part A (subjects 007, 
008, 009, 011, and 014), all with AL amyloidosis and a large liver amyloid load, who were 
the first to receive a second treatment in part B. This reduced the amyloid load, shown by 
SAP scintigraphy, in the spleen of subject 008 and liver of subject 014; liver stiffness was 
reduced in subject 009. There was no SAP scintigraphy change in the liver in subjects 007 
and 011, but liver stiffness was reduced in subject 007. Subject 011 suffered a clonal 
relapse after the initial treatment in part A, which persisted throughout part B. Subjects 
009 and 011 had infusion reactions, subject 014 developed a moderate rash, and subject 
008 had a serious adverse event: hypotension during dezamizumab infusion leading to a 
temporary rise in creatinine concentration. After this event, routine premedication with 
100­mg hydrocortisone and a nonselective antihistamine was administered to all subjects 
before each dezamizumab dose. 
In part A, reduction of renal amyloid was observed in subject 012 who had no liver 
involvement. To determine, in part B, whether the treatment could remove renal amyloid, 
we studied patients with AFib amyloidosis, which always involves the kidneys but typically 
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has a small to moderate whole­body amyloid load. AL amyloidosis commonly affects the 
kidneys, but evaluation is complicated by extensive multisystem involvement. Subject 005, 
who had received only 78 mg of dezamizumab early in part A, was scheduled to receive 
600 mg in part B, but the infusion was stopped as a precautionary measure at 330 mg, 
because subject 008, being treated at the same time, became hypotensive after 
dezamizumab infusion. Renal amyloid was not reduced in subject 005 after this dose or 
in subject 004 after 600 mg, but the load was reduced in both cases after a subsequent 
dose of 1200 mg. Renal amyloid load was also reduced after 1200 mg of dezamizumab 
in each of the other AFib subjects, 002, 006, and 017. 
Dezamizumab doses of 1000 or 1200 mg had little effect on the hepatic amyloid load 
in subjects 007, 010, 011, 015, and 016 with AL amyloidosis and 009 with AApoAI type, 
all of whom had a large liver and whole­body amyloid load. However, a subsequent 
2000­mg dose reduced the liver and/or spleen amyloid in all except subject 011 who was 
in clonal relapse. Subject 019, also with a very heavy liver and whole­body AL amyloid 
load, received 2000­mg dezamizumab as the first dose, but no amyloid reduction was 
detected and the subject was unable to receive a second dose before the study closed. 
Subjects with known cardiac amyloidosis were excluded from part A, but after 
amyloid clearance from multiple organs with acceptable safety and tolerability during part 
B, protocol amendment allowed enrolment of six subjects with mild but definite cardiac 
involvement, three with AL and three with ATTR type, for preliminary safety assessment. 
Four subjects received one treatment and two subjects received three treatments. 
Dezamizumab infusion was split over two consecutive days and cardiac safety was closely 
monitored. The study ended after treatment of the cardiac subjects because the study 
objectives had been achieved, the supply of dezamizumab was exhausted, and it had 
become evident that serial repeated treatments, with miridesap followed by doses of 
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dezamizumab appropriate for the amyloid load in each individual, would be required to 
optimize amyloid clearance. 
 
Study measures 
Comprehensive hematological, biochemical, cardiac, renal, and immunological tests were 
performed at screening, baseline before dosing, during dezamizumab infusion, the 
subsequent inpatient days, and, if not still an inpatient, on study days 6, 14, and 21, with 
final follow­up on day 42, along with blood sampling for pharmacokinetic studies. Amyloid 
load was monitored as follows. Liver stiffness was measured by transient elastography 
(18, 19) at baseline and days 14 and 42. Extra­ cellular volumes of the heart, liver, and 
spleen were measured by equilibrium MRI (20–22) at baseline and day 42. 123I­SAP 
scintigraphy with computed tomography (CT)–single photon emission CT (CT­ SPECT) to 
quantify organ retention of tracer at 24 hours (24) was performed at baseline and day 42, 
when the soluble and amyloid­bound SAP pools had fully re­equilibrated. ATTR 
amyloidosis subjects underwent 99mTc­3,3­diphosphono­1,2­propanodicarboxylic acid 
(99mTc­DPD) CT­SPECT scintigraphy at baseline and day 42 to quantify cardiac ATTR 
amyloid (25). EKGs were monitored by Holter 24­hour recordings on the first day of 
miridesap infusion, by telemetry during dezamizumab infusion, and by Holter on study 
days 1 and 3 thereafter. 
 
Study outcomes 
In addition to the primary safety outcome measure, dezamizumab pharmacokinetics, 






Safety and pharmacokinetic outcomes were assessed without formal hypothesis testing. 
Changes in absolute values and proportional changes from baseline in the different 
measures of amyloid load were evaluated in relation to the reference ranges and variances 
of the respective tests. 
 
SUPPLEMENTARY MATERIALS 
Table S1. Demographic features of participants, amyloid type and load, dezamizumab 
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Median normal ECV, 0.29; liver stiffness, 5.3 kPa (90% < 7.0 kPa); GGT, γ glutamyl transpeptidase, 5-45 IU/L. 
These 10 subjects were those who had definite detectable hepatic amyloidosis.  Subjects 011 and 013 entered clonal relapse after 
first dosing session.  Subject 014 suffered clonal relapse after second dose and developed rash in session 3, thus receiving only half 
the planned 1,000 mg dose. 

































Table 2.  Effect of Dezamizumab on Measures of Cardiac Amyloid 
Subject Number 
Amyloid Type 

































ATTR 1,200 248 255 
Perugini grade 2 
cardiac uptake.  No 
change 
024 
ATTR 1,000 255 260 
Perugini grade 2 
cardiac uptake.  No 
change 
025 
ATTR 600 196 205 
Perugini grade 2 
cardiac uptake.  No 
change 
 






Fig. 1.  Pharmacokinetics of Dezamizumab.  Subject 013 received 650 mg of dezamizumab in 
Session 1 (Part A) () and 600 mg in Session 2 (Part B) ().  Subject 016 received an ineffective 
first antibody dose in Part A but then an effective second dose of 2000 mg in Session 2 (Part B) 
(▲)followed by a further 2000 mg dose (in Session 3 (Part B) (). 
 
Fig. 2.  Effect on Amyloid Load of Treatment with Miridesap plus Dezamizumab.  (A) Anterior 
SAP scintigraphy scans of subject 014 with systemic AL amyloidosis.  Before treatment, left; 42 
days after first dezamizumab dose, center; 42 days after second dezamizumab dose, right.  (B) 
Posterior SAP scintigraphy scans of subject 017 with hereditary systemic AFib amyloidosis.  
Before treatment, left; 42 days after dezamizumab, right. 
 
Fig. 3  Effect on Liver Stiffness and NT-proBNP of Treatment with Miridesap plus 
Dezamizumab.  (A) Serial measurements of liver stiffness by transient elastography after start of 
dezamizumab infusion on day 1 in subjects with hepatic amyloidosis.  PD, pre­dose measurement 
before each dezamizumab infusion.  Median normal liver stiffness, 5.3 kPa (90% < 7.0 kPa).  
Upper panel: subjects with initial baseline stiffness ≤15kPa.  Subject 007 () received sequential 
doses of 152, 600 and 2,000 mg dezamizumab.  Subject 008 () 246, 600 mg.  Subject 013 () 
650, 600 mg.  Subject 014 (□) 600, 1,000, 500 mg.  Subject 015 () 600, 2,000 mg.  Lower panel: 
subjects with initial baseline stiffness >15kPa.  Subject 009 (▲) 637, 1,000, 2,000 mg.  Subject 
010 (▼) 400, 1,200, 2,000 mg.  Subject 011 () 650, 1,000, 2,000 mg).  Subject 016 (∇) 600, 
2,000, 2,000 mg.  Subject 019 () 2,000 mg.  The interval between doses was variable: range 
3­12 months. (B) Serial measurements of circulating NT­proBNP after dezamizumab treatment in 
subjects with proven cardiac amyloidosis.  All available results are shown.  S, value at screening 
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before study; PD, pre­dose value before each dezamizumab infusion; results after first dose 
shown on an expanded scale.  Subject 018 (AL type) () received sequential doses of 600, 1,200, 
1,200 mg dezamizumab.  Subject 020 (AL) (□) 600 mg.  Subject 021 (AL) (▲) 600, 1,200, 
1,200 mg.  Subject 023 (ATTR) () 1,200 mg.  Subject 024 (ATTR) () 1,000 mg).  Subject 025 























Making amyloid vanish 
Fatal systemic amyloidosis is caused by extracellular amyloid deposition that disrupts tissue 
structure and function. The normal plasma protein, serum amyloid P component (SAP), is 
always present within amyloid deposits. Richards et al. now show that previous depletion of 
circulating SAP by the drug, miridesap, uniquely enables subsequent administration of the 
humanized anti­SAP antibody, dezamizumab, to patients with systemic amyloidosis. 
Dezamizumab bound to residual SAP in the amyloid deposits and triggered their removal. 
Repeat cycles of miridesap followed by dezamizumab progressively removed amyloid from the 
liver, spleen, and kidneys of the patients. Evidence of clinical benefit suggests that this new 
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Fixed dose per escalation 
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Preferred dose for renal 
amyloid, associated with higher 
response rate than 600 mg 
 























Evaluation of 600 mg dose in 





Preferred dose for renal amyloid, 
associated with higher response 













1 mg/kg per escalation plan 
 
330 (600 mg 
planned)d 
 
Evaluation of 600 mg dose in 
subjects with renal amyloid 
 
1,200 
Preferred dose for renal amyloid, 
associated with higher response 













1 mg/kg per escalation plan 
 
1,200 
Preferred dose for renal 
amyloid, associated with higher 
response rate than 600 mg 
 












3 mg/kg per escalation plan 
 
600 
Evaluation of 600 mg in 










Moderate liver, large spleen, 












Evaluation of 600 mg in AL with 
hepatic amyloid 
 
No third dose after serious adverse effect with 
dose 2 
 






637 10 mg/kg per escalation plan 
 
1,000 Evaluation of 1,000-1,200 mg in hepatic amyloid 
 












Dose reduced owing to 
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Large spleen, small kidney and 







Repeat evaluation of 
650 mg following response 
in subject 011 
 
Further dosing awaiting additional information about potential effect of SAA response to antibody 





Large liver; moderate spleen; 
small kidney, bone marrow; 










Repeat evaluation of 
650 mg following 






Dose repeated as good 
response to dose 1 
 
Left study due to clonal relapse and referral for 

















Responses in subjects 011- 
013 but also infusion 
reactions. 300mg + 300 mg 














Good response to dose 2 so repeat 
intended but dosing interrupted by 
rash 
 






600 Repeat evaluation as for subject 014 
 
2,000 Dose escalation as no response to 600 mg 
 
Unable to return before study end 
 






600 Repeat evaluation as for subject 014 
 
2,000 Dose escalation as no response to 600 mg 
 
















Preferred dose for renal 
amyloid, associated with 









Small spleen. Interventricular 
septum 15 mm. Ejection 



























Repeat dose. No escalation due to 
rash 
 






2,000 High dose as large hepatic amyloid load present 
 






Small kidney, moderate spleen, 
small adrenals. LVf non- 
dilated, normal systolic 
function, ejection fraction 72%, 

























































Small kidney, moderate spleen. 
Preserved systolic function; 
impaired longitudinal 
contraction; grade 2 diastolic 
dysfunction; wall 17 mm; 




















































Evaluation of 1,200 mg in 
cardiac ATTR as 600 mg 
well tolerated in previous 
cardiac amyloidosis cases 
 
 

















Evaluation of 1,000 mg in 
cardiac ATTR as 600 mg 
well tolerated in previous 
cardiac amyloidosis cases 
 
 

















Evaluation of 1,200 mg in 
cardiac ATTR as 600 mg 
well tolerated in previous 
cardiac amyloidosis cases 
 
 
Unable to return before study end 
a  Subjects 001- 016 participated in part A and all except 001 and 012 also participated in part B; subjects 017-025 were in part B only.    Subjects 003 and 022 were screened but not enrolled due to poor venous 
access and scheduling difficulties respectively. 
b  Amyloidosis nomenclature: AA, amyloid A protein type; ApoAI, apolipoprotein AI type, AFib, fibrinogen A α-chain type, AL, monoclonal immunoglobulin light chain type, ATTR, transthyretin type. 
c  Maximum of 3 treatment sessions in Parts A and B. Doses shown are as planned unless administered doses differed greatly. 
d  Dosing stopped because subject 008, being treated at the same time, experienced a serious adverse effect. 
e  Dosing stopped due to onset of rash. 
f   LV, left ventricle. 
 
